

# A Kidney Graft Survival Calculator that Accounts for Mismatches in Age, Sex, HLA, and Body Size

Valarie B. Ashby,\* Alan B. Leichtman,<sup>†</sup> Michael A. Rees,<sup>‡</sup> Peter X.-K. Song,\* Mathieu Bray,\* Wen Wang,\* and John D. Kalbfleisch\*

## Abstract

**Background and objectives** Outcomes for transplants from living unrelated donors are of particular interest in kidney paired donation (KPD) programs where exchanges can be arranged between incompatible donor-recipient pairs or chains created from nondirected/altruistic donors.

**Design, setting, participants, & measurements** Using Scientific Registry of Transplant Recipients data, we analyzed 232,705 recipients of kidney-alone transplants from 1998 to 2012. Graft failure rates were estimated using Cox models for recipients of kidney transplants from living unrelated, living related, and deceased donors. Models were adjusted for year of transplant and donor and recipient characteristics, with particular attention to mismatches in age, sex, human leukocyte antigens (HLA), body size, and weight.

**Results** The dependence of graft failure on increasing donor age was less pronounced for living-donor than for deceased-donor transplants. Male donor-to-male recipient transplants had lower graft failure, particularly better than female to male (5%–13% lower risk). HLA mismatch was important in all donor types. Obesity of both the recipient (8%–18% higher risk) and donor (5%–11% higher risk) was associated with higher graft loss, as were donor-recipient weight ratios of <75%, compared with transplants where both parties were of similar weight (9%–12% higher risk). These models are used to create a calculator of estimated graft survival for living donors.

**Conclusions** This calculator provides useful information to donors, candidates, and physicians of estimated outcomes and potentially in allowing candidates to choose among several living donors. It may also help inform candidates with compatible donors on the advisability of joining a KPD program.

*Clin J Am Soc Nephrol* 12: 1148–1160, 2017. doi: <https://doi.org/10.2215/CJN.09330916>

## Introduction

Graft survival after kidney transplantation is of considerable interest to donors, candidates, health professionals, and payers. We examine the donor and recipient characteristics that are associated with graft survival for transplants from living related (LR), living unrelated (LUR), and deceased donors (DD), and develop models that are useful in estimating outcomes on the basis of these characteristics.

It is well known that characteristics of both donors and recipients are related to outcomes and there have been numerous studies that examine these relationships, especially with regard to donor and recipient age and human leukocyte antigen (HLA) mismatch (MM). Except for HLA MM, previous studies have generally considered donor and candidate characteristics separately, and most studies have been confined to either DDs or living donors (LDs) (1–21). A pediatric study reported on differences in graft survival for all three types of donors, but did not examine other factors (22). On the basis of a 15-year time period, we examine graft survival as a function of donor and recipient age, sex, HLA MM, and body size with an emphasis on the outcome's possible dependence

on MMs between donors and recipients. These results are used to develop a calculator that estimates the probabilities of graft survival at 5 and 10 years on the basis of recipient and donor characteristics. This study was partially motivated by consideration of kidney paired donation (KPD) programs, where all transplants are from LUR donors (23–26). This provides useful information to candidates, donors, and physicians, but has particular possible benefit in helping to guide decisions, where, for example, a candidate might have the opportunity to choose between several LDs, or a candidate with a compatible LD might join a KPD program to find another donor predicted to yield better post-transplant outcomes. The incorporation of compatible pairs in a KPD program can also be beneficial to other candidates in the program (25,26).

## Materials and Methods

This study used data on a 15-year cohort of 232,705 kidney-alone transplant recipients from 1998 to 2012 from the Scientific Registry of Transplant Recipients (SRTR). The SRTR system includes data on all donors, wait-listed candidates, and transplant recipients in the

\*Department of Biostatistics, University of Michigan, Ann Arbor, Michigan; <sup>†</sup>Arbor Research Collaborative for Health, Division of Nephrology, University of Michigan, Ann Arbor, Michigan; and <sup>‡</sup>Departments of Urology and Pathology, University of Toledo Medical Center, Toledo, Ohio

**Correspondence:** Prof. John D. Kalbfleisch, Kidney Epidemiology and Cost Center, The University of Michigan, 1415 Washington Heights, Suite 3645 SPH I, Ann Arbor, MI 48109-2029. Email: [jdkalbfl@umich.edu](mailto:jdkalbfl@umich.edu)

United States, submitted by the members of the Organ Procurement and Transplantation Network (OPTN). The Health Resources and Services Administration, US Department of Health and Human Services, provides oversight to the activities of its OPTN and SRTR contractors.

Analyses were performed separately for three donor types: LR, LUR, and DD. Transplants were considered to be LR if there was a biologic relationship between the donor and recipient. LD transplants with a pediatric donor or an unknown relationship between donor and recipient were excluded ( $n=97$ ). Five- and 10-year rates of graft failure were estimated for transplants from 32,349 LUR donors, 56,660 LR donors, and 143,696 DD. The origin for analysis was the time of transplant and the event of interest was the first of graft failure or death. Patients were censored at December 31, 2013 or at loss to follow-up. All models were adjusted for transplant year, ESRD cause, panel reactive antibody at transplant, previous transplant, years of ESRD, hepatitis C serology, insurance, recipient and donor race and ethnicity, donor history of cigarette use, and the following donor-recipient combinations: age, sex, obesity status (body mass index  $\geq 30$ ), weight ratio, height ratio, HLA MM, and ABO compatibility. These models concentrate attention on the potential association with MM between donor and recipient and, in so doing, account for interactions between donor and recipient characteristics. Results are presented in terms of hazard ratios (HR) and 5- or 10-year graft survival rates and are on the basis of the Cox model (27). For a given donor and recipient, these models inform a calculator that estimates the probability of surviving with a functioning graft 5 and 10 years post-transplant. For 10-year outcomes in the calculator, the Cox model was stratified into two time segments from 0 to 5 years and 5 to 10 years with separate

relative risk parameters for each segment. The 10-year graft survival probability given by the calculator is the product of the probability of graft survival for the first 5 years with the probability of survival for the second 5 years given the first.

### Results

Figure 1 shows the probability of graft failure at 5 years for each donor type and transplant year from 1998 to 2008. Among transplants performed from 1998 to 2000, the average 5-year graft failure was 33%, 21%, and 20% for DD, LUR, and LR transplant recipients, respectively. For transplant recipients from 2006 to 2008, these average failure probabilities were substantially reduced to 28%, 16%, and 15%, respectively. It is important to account for this trend in the models and in the calculator developed in this paper.

Table 1 presents the counts, distribution, and comparative risks of graft failure for the first 5 post-transplant years on the basis of separate models for three donor groups, LUR, LR, and DD. Results concentrate on five characteristics of particular interest that relate to donor/recipient MM: age, sex, HLA differences, body mass index, and weight.

### Age

Table 1 shows that the distributions of both recipient and donor age differ across the three donor types, although the recipient age distributions for LUR donors and DDs are similar. For all three classes of donors, the risk of graft failure is higher within the 13–17, 18–29, and 60+ years recipient age categories. Tables 2–5 show the estimated probability of graft failure at 5 and 10 years by donor-recipient age groups for LD and DD transplant recipients.




Figure 1. | Trends in the unadjusted probability of graft failure at 5 years for deceased donor, living unrelated donor, and living related transplant recipients, 1998–2008. Graft failure probabilities shown for years in which five years of followup is available.

Table 1. Adjusted risk of graft failure at 5 years by characteristic for each transplant donor type for transplants from 1998 to 2012

Characteristic <sup>a</sup>	LUR Donor (n=32,349)		LR Donor (n=56,660)		Deceased Donor (n=143,696)	
	N (%)	HR (95% CI)	N (%)	HR (95% CI)	N	HR (95% CI)
Recipient age, yr						
<13	316 (1)	1.12 (0.77 to 1.63)	2594 (5)	1.01 (0.88 to 1.16)	2791 (2)	1.40 (1.28 to 1.54)
13-17	304 (1)	2.49 (1.93 to 3.21)	2123 (4)	2.02 (1.80 to 2.26)	3454 (2)	2.05 (1.90 to 2.20)
18-29	2577 (8)	1.72 (1.53 to 1.94)	9104 (16)	1.59 (1.48 to 1.72)	9461 (7)	1.48 (1.41 to 1.55)
30-39	5384 (17)	1.11 (1.00 to 1.23)	9818 (17)	1.10 (1.02 to 1.19)	18,601 (13)	1.10 (1.06 to 1.14)
40-49	8709 (27)	1.00 (Ref)	11,019 (19)	1.00 (Ref)	29,918 (21)	1.00 (Ref)
50-59	9031 (28)	1.08 (0.99 to 1.18)	11,853 (21)	1.10 (1.02 to 1.18)	39,454 (28)	1.12 (1.09 to 1.16)
60+	6028 (19)	1.57 (1.43 to 1.73)	10,149 (18)	1.39 (1.29 to 1.50)	40,017 (28)	1.46 (1.41 to 1.51)
Donor age, yr						
<18	—	—	—	—	18,812 (13)	0.78 (0.75 to 0.81)
18-29	4141 (13)	0.88 (0.80 to 0.98)	12,609 (22)	0.89 (0.84 to 0.95)	33,500 (23)	0.76 (0.73 to 0.79)
30-39	7845 (24)	0.93 (0.85 to 1.01)	17,090 (30)	0.92 (0.87 to 0.98)	20,835 (15)	0.84 (0.81 to 0.87)
40-49	10,448 (32)	1.00 (Ref)	16,472 (29)	1.00 (Ref)	30,744 (21)	1.00 (Ref)
50-59	7698 (24)	1.14 (1.05 to 1.24)	8691 (15)	1.07 (1.00 to 1.14)	27,289 (19)	1.20 (1.17 to 1.24)
60+	2217 (7)	1.38 (1.23 to 1.56)	1798 (3)	1.42 (1.26 to 1.59)	12,516 (9)	1.52 (1.46 to 1.58)
Donor-recipient sex						
Female-female	5828 (18)	1.01 (0.92 to 1.11)	14,549 (26)	1.07 (1.00 to 1.14)	23,567 (16)	0.93 (0.89 to 0.96)
Male-female	5922 (18)	1.07 (0.96 to 1.19)	9371 (17)	1.03 (0.95 to 1.12)	33,227 (23)	0.94 (0.91 to 0.98)
Female-male	14,765 (46)	1.00 (Ref)	17,773 (31)	1.00 (Ref)	34,420 (24)	1.00 (Ref)
Male-male	5834 (18)	0.87 (0.79 to 0.95)	14,967 (26)	0.89 (0.83 to 0.95)	52,482 (37)	0.95 (0.92 to 0.98)
HLA ABDR mismatch						
0 MM	162 (1)	0.69 (0.42 to 1.12)	7869 (14)	0.62 (0.57 to 0.67)	15,171 (11)	0.83 (0.80 to 0.86)
1-2 MM, 0 DR MM	847 (3)	0.73 (0.59 to 0.91)	8512 (15)	0.93 (0.88 to 1.00)	5796 (4)	0.87 (0.82 to 0.92)
1-2 MM, 1-2 DR MM	993 (3)	0.85 (0.70 to 1.02)	10,308 (18)	0.95 (0.89 to 1.01)	6103 (4)	0.95 (0.90 to 1.00)
3-4 MM, 0 DR MM	1350 (4)	0.91 (0.77 to 1.06)	532 (1)	0.99 (0.79 to 1.24)	10,557 (7)	0.91 (0.87 to 0.95)
3-4 MM, 1-2 DR MM	12,149 (38)	1.00 (Ref)	23,413 (41)	1.00 (Ref)	44,692 (31)	1.00 (Ref)
5,6, missing MM	16,848 (52)	1.06 (1.00 to 1.13)	6026 (11)	1.06 (0.99 to 1.14)	61,377 (43)	1.08 (1.06 to 1.11)
Recipient BMI (kg/m <sup>2</sup> )						
Not obese (<30)	20,508 (63)	1.00 (Ref)	36,876 (65)	1.00 (Ref)	88,565 (62)	1.00 (Ref)
Obese (>30)	8637 (27)	1.18 (1.09 to 1.28)	12,112 (21)	1.15 (1.08 to 1.22)	37,269 (26)	1.08 (1.05 to 1.11)
Missing	3204 (10)	1.03 (0.89 to 1.19)	7672 (14)	1.17 (1.07 to 1.28)	17,862 (12)	0.93 (0.86 to 1.01)
Donor BMI						
Not obese (<30)	22,355 (69)	1.00 (Ref)	35,679 (63)	1.00 (Ref)	109,771 (76)	1.00 (Ref)
Obese (>30)	6307 (20)	1.11 (1.02 to 1.20)	10,948 (19)	1.05 (0.98 to 1.11)	33,268 (23)	1.07 (1.04 to 1.10)
Missing	3687 (11)	0.94 (0.78 to 1.13)	10,033 (18)	1.08 (0.95 to 1.22)	657 (1)	1.05 (0.90 to 1.22)
Donor-recipient weight ratio						
<0.75	6388 (20)	1.12 (1.01 to 1.25)	6526 (12)	1.09 (1.00 to 1.19)	30,333 (21)	1.12 (1.08 to 1.16)
0.75-0.90	6239 (19)	1.06 (0.96 to 1.16)	8568 (15)	0.98 (0.91 to 1.06)	23,538 (16)	1.04 (1.00 to 1.08)

**Table 1. (Continued)**

Characteristic <sup>a</sup>	LUR Donor (n=32,349)		LR Donor (n=56,660)		Deceased Donor (n=143,696)	
	N (%)	HR (95% CI)	N (%)	HR (95% CI)	N	HR (95% CI)
0.90–1.15	8113 (25)	1.00 (Ref)	14,951 (26)	1.00 (Ref)	35,606 (25)	1.00 (Ref)
>1.15	7606 (24)	1.09 (0.99 to 1.21)	16,193 (29)	0.97 (0.90 to 1.03)	43,162 (30)	1.00 (0.96 to 1.03)
Missing	4003 (12)	1.16 (0.99 to 1.36)	10,422 (18)	1.06 (0.95 to 1.18)	11,057 (8)	1.26 (1.18 to 1.35)
Donor-recipient height ratio						
<0.94	8480 (26)	1.13 (1.01 to 1.27)	8978 (16)	1.08 (0.99 to 1.18)	30,240 (21)	1.05 (1.02 to 1.09)
0.94–1.00	6851 (21)	1.02 (0.92 to 1.13)	11,053 (20)	1.00 (0.93 to 1.08)	29,183 (20)	1.00 (0.97 to 1.03)
1.00–1.06	6180 (19)	1.00 (Ref)	13,042 (23)	1.00 (Ref)	34,057 (24)	1.00 (Ref)
>1.06	5757 (18)	0.96 (0.86 to 1.07)	10,748 (19)	0.98 (0.91 to 1.07)	38,460 (27)	0.94 (0.91 to 0.98)
Missing	5081 (16)	1.04 (0.87 to 1.25)	12,839 (23)	0.91 (0.81 to 1.02)	11,756 (8)	1.11 (1.04 to 1.19)
Recipient race/ethnicity						
White	23,515 (73)	1.00 (Ref)	36,590 (65)	1.00 (Ref)	69,709 (49)	1.00 (Ref)
Black	3930 (12)	1.22 (1.09 to 1.38)	8863 (16)	1.28 (1.06 to 1.53)	43,656 (30)	1.15 (1.12 to 1.18)
Hispanic	3166 (10)	0.96 (0.83 to 1.10)	8391 (15)	0.85 (0.73 to 0.98)	20,065 (14)	0.79 (0.76 to 0.82)
Other	1738 (5)	0.82 (0.71 to 0.96)	2816 (5)	0.67 (0.59 to 0.76)	10,266 (7)	0.75 (0.71 to 0.78)
Donor race/ethnicity						
Not black or Hispanic	26,676 (83)	1.00 (Ref)	39,484 (70)	1.00 (Ref)	105,874 (74)	1.00 (Ref)
Black	2703 (8)	1.12 (0.97 to 1.28)	8708 (15)	1.10 (0.91 to 1.32)	18,700 (13)	1.24 (1.20 to 1.27)
Hispanic	2970 (9)	0.84 (0.73 to 0.97)	8468 (15)	0.91 (0.79 to 1.05)	19,122 (13)	1.02 (0.98 to 1.05)
Donor history of cigarette use						
No	15,537 (48)	1.00 (Ref)	20,611 (36)	1.00 (Ref)	6108 (4)	1.00 (Ref)
Yes	4917 (15)	1.09 (0.99 to 1.20)	6744 (12)	1.08 (0.99 to 1.17)	43,128 (30)	1.09 (1.04 to 1.15)
Missing	11,895 (37)	1.15 (1.05 to 1.26)	29,305 (52)	1.18 (1.10 to 1.27)	94,460 (66)	1.04 (0.99 to 1.10)
ABO compatibility						
Not incompatible	31,895 (99)	1.00 (Ref)	56,086 (99)	1.00 (Ref)	143,374 (100)	1.00 (Ref)
Incompatible	454 (1)	1.51 (1.22 to 1.87)	574 (1)	1.36 (1.11 to 1.66)	322 (0)	1.16 (0.94 to 1.43)
PRA						
0–9	26,473 (82)	1.00 (Ref)	47,022 (83)	1.00 (Ref)	111,404 (78)	1.00 (Ref)
10–79	4079 (13)	1.09 (0.99 to 1.20)	6408 (11)	1.11 (1.03 to 1.19)	21,784 (15)	1.11 (1.07 to 1.14)
80+	730 (2)	1.35 (1.12 to 1.63)	1321 (2)	1.45 (1.27 to 1.65)	8278 (6)	1.27 (1.21 to 1.34)
Missing	1067 (3)	0.87 (0.71 to 1.06)	1909 (3)	0.93 (0.81 to 1.07)	2230 (2)	1.22 (1.10 to 1.34)
Recipient diagnosis						
Not diabetes	25,264 (78)	1.00 (Ref)	45,337 (80)	1.00 (Ref)	110,370 (77)	1.00 (Ref)
Diabetes	7085 (22)	1.32 (1.23 to 1.41)	11,323 (20)	1.30 (1.23 to 1.37)	33,326 (23)	1.27 (1.24 to 1.30)
Previous transplant						
No	28,584 (88)	1.00 (Ref)	51,219 (90)	1.00 (Ref)	125,104 (87)	1.00 (Ref)
Yes	3765 (12)	1.41 (1.29 to 1.55)	5441 (10)	1.16 (1.08 to 1.25)	18,592 (13)	1.19 (1.15 to 1.23)

Table 1. (Continued)

Characteristic <sup>a</sup>	LUR Donor (n=32,349)		LR Donor (n=56,660)		Deceased Donor (n=143,696)	
	N (%)	HR (95% CI)	N (%)	HR (95% CI)	N	HR (95% CI)
Time on dialysis						
Preemptive transplant	10,712 (33)	0.71 (0.65 to 0.77)	18,103 (32)	0.64 (0.60 to 0.68)	16,749 (12)	0.86 (0.82 to 0.90)
0–1 yr	8948 (28)	0.82 (0.75 to 0.89)	17,441 (31)	0.85 (0.80 to 0.91)	15,984 (11)	0.98 (0.94 to 1.02)
1–2 yr	5864 (18)	1.00 (Ref)	10,684 (19)	1.00 (Ref)	21,618 (15)	1.00 (Ref)
2–3 yr	2905 (9)	0.97 (0.86 to 1.08)	4681 (8)	0.99 (0.91 to 1.08)	22,147 (15)	1.03 (0.99 to 1.07)
3+ yr	3920 (12)	1.07 (0.96 to 1.18)	5751 (10)	1.05 (0.97 to 1.13)	67,198 (47)	1.12 (1.08 to 1.15)
Recipient hepatitis C serology						
Negative or missing	31,419 (97)	1.00 (Ref)	55,147 (97)	1.00 (Ref)	134,430 (94)	1.00 (Ref)
Positive	930 (3)	1.51 (1.31 to 1.74)	1513 (3)	1.46 (1.31 to 1.63)	9266 (6)	1.45 (1.40 to 1.51)
Recipient insurance						
Public primary payer	11,346 (35)	1.00 (Ref)	22,824 (40)	1.00 (Ref)	96,508 (67)	1.00 (Ref)
Private primary payer	20,184 (62)	0.77 (0.72 to 0.82)	31,892 (56)	0.80 (0.77 to 0.84)	42,478 (30)	0.82 (0.80 to 0.84)
Other/missing	819 (3)	0.83 (0.69 to 1.01)	1944 (3)	0.92 (0.81 to 1.03)	4710 (3)	0.94 (0.89 to 1.00)
Transplant year						
1998–2002	7013 (22)	1.00 (Ref)	19,810 (35)	1.00 (Ref)	40,977 (29)	1.00 (Ref)
2003–2007	11,609 (36)	0.83 (0.76 to 0.90)	20,553 (36)	0.93 (0.87 to 0.99)	49,191 (34)	0.82 (0.80 to 0.84)
2008–2012	13,727 (42)	0.63 (0.55 to 0.71)	16,297 (29)	0.78 (0.71 to 0.85)	53,528 (37)	0.62 (0.60 to 0.64)

LUR, living unrelated; LR, living related; HR, hazard ratio; 95% CI, 95% confidence interval; Ref, reference group; —, not included in study; MM, mismatch; BMI, body mass index; PRA, panel reactive antibody;

<sup>a</sup>Adjusted for transplant year, ESRD cause, PRA at transplant, previous transplant, years of ESRD, hepatitis C serology, insurance, and recipient and donor race and ethnicity, donor history of cigarette use, and the following donor-recipient combinations: age, sex, obesity status, weight ratio, height ratio, HLA mismatch, and ABO compatibility.

**Table 2. Adjusted probability (and 95% confidence interval) of graft failure at 5 years by donor-recipient age group for living-donor transplant recipients, 1998–2012**

Donor Age <sup>a</sup> (yr)	Recipient Age (yr)					
	<18	18–29	30–39	40–49	50–59	60+
18–29	19.4 (16.5 to 22.1)	18.1 (16.8 to 19.5)	13.8 (12.4 to 15.1)	12.7 (11.5 to 13.9)	12.7 (11.6 to 13.7)	16.0 (14.0 to 17.9)
30–39	17.3 (15.4 to 19.2)	20.3 (18.3 to 22.2)	13.2 (12.3 to 14.1)	13.1 (12.0 to 14.1)	13.5 (12.5 to 14.5)	17.0 (15.8 to 18.1)
40–49	20.5 (18.2 to 22.8)	23.8 (22.1 to 25.5)	14.7 (13.3 to 16.0)	12.3 (11.6 to 13.0)	13.7 (12.7 to 14.7)	19.3 (18.1 to 20.4)
50–59	21.5 (16.1 to 26.5)	22.0 (20.0 to 24.0)	16.3 (14.5 to 18.0)	13.8 (12.3 to 15.2)	15.6 (14.6 to 16.6)	20.2 (18.5 to 21.9)
60+	Not shown <sup>b</sup>	26.2 (17.5 to 34.1)	20.5 (16.9 to 23.9)	18.5 (14.6 to 22.3)	18.9 (15.7 to 22.0)	25.6 (23.3 to 27.8)

<sup>a</sup>Adjusted for transplant year, ESRD cause, panel reactive antibody at transplant, previous transplant, years of ESRD, hepatitis C serology, insurance, and recipient and donor race and ethnicity, donor history of cigarette use, and the following donor-recipient combinations: sex, obesity status, weight ratio, height ratio, HLA mismatch, and ABO compatibility. Each probability pertains to the average donor and recipient characteristic for each model.

<sup>b</sup>Because of small cell size, graft failure results are not shown for the pediatric age group (<18) with donors of age 60 years or older.

The LR and LUR groups were merged into one group because they have similar graft failure rates.

For DD transplant recipients of all age groups, receipt of a kidney from a donor 60 years or older was associated with the greatest probability of graft loss. For recipients of LD transplants, graft failure with increasing donor age was not as pronounced as it was with recipients of DD transplants. The youngest and oldest recipient groups showed the highest 5-year graft failure. Similarly, for recipients of LDs, Figure 2 gives a graph of estimated HRs of graft failure by donor and recipient age group relative to the reference group. In the model for the calculator, the log HR of age of donor is modeled, conditional on the age of recipient, as a series of connected straight lines as illustrated in Figure 2. This has the effect of smoothing the dependence on donor age in the calculator, so that donors who are close in age have similar estimates of graft survival, a desirable feature in comparing potential donors for a given candidate.

**Sex**

Among LDs, the combination of a male donor and male recipient had better graft survival than all other donor-recipient combinations (Table 1). Male recipients with a male LUR donor had a 13% lower overall risk of graft failure (HR, 0.87; 95% confidence interval [95% CI], 0.79 to 0.95) compared with male recipients who received a kidney from a female LUR donor. These differences exist despite adjustment for donor and recipient body size and the other listed recipient and donor characteristics.

This dependence is also reflected in the probability of graft failure at 5 and 10 years by donor-recipient sex as shown in Figure 3. At 5 years for the LUR and LR donor types, male donor-to-male recipient transplants had lower graft failure (13.6% and 14.0%) compared with all other donor-recipient combinations and, in particular, lower graft failure than female donor-to-male recipient transplants (15.8% both LD categories). Among recipients of DDs, female donors to male recipients have the highest graft failure (29.0%) compared with all other donor-recipient combinations (26.6%–27.5%). Similar trends are also shown for graft failure at 10 years.

**HLA MM**

For all donor types, recipients of a zero MM kidney had the lowest risk of graft failure (Table 1). Recipients with 0 MM make up about 14% and 11% of the LR donor and the DD groups, respectively, but <1% of the LUR donor group. The high frequency in the DD group is due to the preference given to such transplants for candidates on the DD wait list. Those recipients with a 1–2 HLA MM and a 0 DR MM have a 7%–27% lower risk of graft failure when compared with the reference group (3–4 HLA MM with a 1–2 DR MM) across all donor types. However, most LUR transplant recipients (93%) have a 3–6 or unknown HLA MM. Recipients with 5–6 or unknown HLA MM have the highest risk of graft failure in all donor groups.

**Body Size**

For all donor groups, Table 1 shows that obesity of either the recipient or donor was associated with a higher probability of graft loss. Obese LUR, LR, and DD recipients had



**Table 3. Adjusted probability (and 95% confidence interval) of graft failure at 10 years by donor-recipient age group for living-donor transplant recipients, 1998–2012**

Donor Age <sup>a</sup> (yr)	Recipient Age (yr)					
	<18	18–29	30–39	40–49	50–59	60+
18–29	35.3 (31.0 to 39.3)	33.8 (31.7 to 35.9)	27.4 (25.2 to 29.6)	27.4 (25.3 to 29.4)	31.5 (29.4 to 33.6)	40.1 (36.2 to 43.8)
30–39	35.1 (32.1 to 38.0)	38.1 (35.2 to 41.0)	26.4 (24.9 to 27.8)	26.9 (25.2 to 28.7)	30.5 (28.8 to 32.3)	40.2 (38.1 to 42.2)
40–49	40.9 (37.3 to 44.3)	44.5 (42.0 to 46.9)	28.8 (26.6 to 30.9)	27.1 (25.7 to 28.3)	30.6 (28.8 to 32.4)	46.0 (43.8 to 48.2)
50–59	45.9 (37.1 to 53.5)	41.1 (38.0 to 44.1)	34.6 (31.6 to 37.5)	31.2 (28.6 to 33.7)	34.8 (33.0 to 36.6)	48.0 (44.7 to 51.2)
60+	Not shown <sup>b</sup>	44.0 (29.4 to 55.6)	38.1 (32.6 to 43.2)	40.5 (33.8 to 46.6)	41.0 (35.1 to 46.3)	52.3 (48.1 to 56.1)

<sup>a</sup>Adjusted for transplant year, ESRD cause, panel reactive antibody at transplant, previous transplant, years of ESRD, hepatitis C serology, insurance, and recipient and donor race and ethnicity, donor history of cigarette use, and the following donor-recipient combinations: sex, obesity status, weight ratio, height ratio, HLA mismatch, and ABO compatibility. Each probability pertains to the average donor and recipient characteristic for each model.

<sup>b</sup>Because of small cell size, graft failure results are not shown for the pediatric age group (<18) with donors of age 60 years or older.

an 18%, 15%, and 8% higher risk of graft failure, respectively, than those LUR, LR, and DD recipients who were not obese. Similarly, recipients with obese donors had a 5%–11% higher risk of failure than those recipients who did not have an obese donor. Table 6 shows the majority of kidney transplant recipients are not obese and do not have an obese donor. Recipients who are both obese and have an obese donor have the highest probability of graft failure. If a donor weighed <75% of the recipient's weight, the recipient had a 9%–12% higher overall risk of graft failure than if the donor and recipient were of similar weight (Table 1). These differences are seen while accounting for the effects of sex and obesity on graft failure as well as recipient and donor height and age.

### Using Estimates to Assess and Compare Donor-Recipient Outcomes

On the basis of the model described above, we developed a calculator that estimates the probability of graft survival given the characteristics of the candidate and potential donor. The parameter estimates for graft failure derived from the LD model are shown in Supplemental Table 1. LR and LUR models were combined and a covariate for LD type (unrelated, related first-degree, related second-degree) was added to the model. The recipient and donor age were fitted using splines as described above. The C-statistic for the 5-year model is 0.64, which compares favorably with other models for graft survival (2,28,29). It should be noted that the C-statistic estimates the probability that the model would allow us to correctly predict which of two randomly chosen individuals would fail first. It does not, however, reflect the ability of the model to discriminate between particular individuals in the population (28,30).

The following example in Table 7 illustrates the use of this calculator in a hypothetical situation of a 50-year-old male candidate with three potential donors. Donor 1 is a 55-year-old sister who is not obese and the donor-recipient weight ratio is 0.70. They have a 3 HLA ABDR MM and 1 DR MM. Donor 2 is not related and is a 25-year-old man. He is not obese, but the donor weight ratio is 1.20. They have a 2 HLA ABDR MM and 2 DR MM. Donor 3 is also not related and is a 35-year-old woman. She is obese and the donor weight ratio is 0.95. They have a 5 ABDR MM with a 2 DR MM. In this example, the graft failure at 5 years is estimated to be 16.0% (95% CI, 14.2% to 17.8%) for donor 1, his sister; 9.8% (95% CI, 8.6% to 11.0%) for donor 2, a much younger man who is less well matched; and 13.6% (95% CI, 12.1% to 15.1%) for donor 3, a much younger woman, also less well matched and obese. At 5 years, there is a clear preference for the candidate to select donor 2 and take advantage of the lower risk of graft failure. At 10 years, although the estimated graft failure probability is much lower for donor 2 than donor 1, the difference is not statistically significant. The computation of the graft survival estimates is shown in the footnote of Table 7.

### Discussion

This calculator has particular potential as a guide to candidates with a compatible LD who may be able to improve their predicted graft or patient survival through participation in a KPD program. Candidates with a compatible donor could

**Table 4. Adjusted probability (and 95% confidence interval) of graft failure at 5 years by donor-recipient age group for deceased-donor transplant recipients, 1998–2012**

Donor age <sup>a</sup> (yr)	Recipient Age (yr)					
	<18	18–29	30–39	40–49	50–59	60+
<18	32.7 (30.1 to 35.2)	27.5 (25.3 to 29.6)	21.5 (19.9 to 23.1)	18.2 (17.0 to 19.5)	20.7 (19.4 to 22.0)	29.1 (27.3 to 30.7)
18–29	33.2 (30.8 to 35.5)	29.7 (27.7 to 31.6)	21.0 (19.8 to 22.3)	19.0 (18.0 to 20.0)	20.6 (19.7 to 21.6)	26.4 (25.1 to 27.5)
30–39	34.9 (30.9 to 38.7)	32.4 (29.8 to 35.0)	23.2 (21.6 to 24.8)	21.0 (19.8 to 22.3)	22.1 (21.0 to 23.3)	28.5 (27.0 to 30.0)
40–49	37.8 (32.4 to 42.8)	32.2 (29.8 to 34.5)	26.9 (25.5 to 28.4)	23.8 (22.7 to 24.9)	26.7 (25.7 to 27.7)	34.4 (33.2 to 35.6)
50–59	40.4 (30.9 to 48.6)	39.9 (36.4 to 43.2)	29.5 (27.7 to 31.3)	29.2 (27.8 to 30.5)	31.0 (29.9 to 32.1)	37.5 (36.3 to 38.6)
60+	Not shown <sup>b</sup>	48.1 (39.5 to 55.4)	39.9 (35.2 to 44.3)	36.5 (33.7 to 39.2)	36.7 (35.0 to 38.4)	44.0 (42.6 to 45.3)

<sup>a</sup>Adjusted for transplant year, ESRD cause, panel reactive antibody at transplant, previous transplant, years of ESRD, hepatitis C serology, insurance, and recipient and donor race and ethnicity, donor history of cigarette use, and the following donor-recipient combinations: sex, obesity status, weight ratio, HLA mismatch, and ABO compatibility. Each probability pertains to the average donor and recipient characteristic for each model.

<sup>b</sup>Because of small cell size, graft failure results are not shown for the pediatric age group (<18) with donors of age 60 years or older.


**Table 5. Adjusted probability (and 95% confidence interval) of graft failure at 10 years by donor-recipient age group for deceased-donor transplant recipients, 1998–2012**

Donor Age <sup>a</sup> (yr)	Recipient Age (yr)					
	<18	18–29	30–39	40–49	50–59	60+
<18	49.4 (45.9 to 52.7)	44.3 (41.3 to 47.2)	37.4 (35.0 to 39.6)	35.0 (33.0 to 36.9)	41.3 (39.2 to 43.3)	54.8 (52.3 to 57.2)
18–29	55.5 (51.9 to 58.9)	47.8 (45.1 to 50.4)	37.8 (35.9 to 39.7)	36.7 (35.1 to 38.2)	40.6 (39.0 to 42.1)	52.4 (50.4 to 54.3)
30–39	61.6 (55.9 to 66.6)	51.3 (47.7 to 54.7)	42.4 (39.9 to 44.8)	40.0 (38.0 to 42.0)	43.6 (41.6 to 45.5)	55.3 (52.9 to 57.6)
40–49	61.0 (54.7 to 66.4)	52.9 (49.6 to 55.9)	46.9 (44.7 to 48.9)	45.0 (43.2 to 46.6)	49.6 (48.0 to 51.2)	62.5 (60.6 to 64.3)
50–59	60.9 (50.3 to 69.3)	58.3 (53.9 to 62.2)	50.5 (47.9 to 52.9)	50.5 (48.6 to 52.4)	56.3 (54.6 to 57.9)	66.7 (64.8 to 68.4)
60+	Not shown <sup>b</sup>	71.4 (61.6 to 78.7)	60.9 (55.1 to 65.9)	61.8 (58.0 to 65.3)	61.3 (58.8 to 63.6)	73.0 (71.0 to 74.8)


<sup>a</sup>Adjusted for transplant year, ESRD cause, panel reactive antibody at transplant, previous transplant, years of ESRD, hepatitis C serology, insurance, and recipient and donor race and ethnicity, donor history of cigarette use, and the following donor-recipient combinations: sex, obesity status, weight ratio, HLA mismatch, and ABO compatibility. Each probability pertains to the average donor and recipient characteristic for each model.

<sup>b</sup>Because of small cell size, graft failure results are not shown for the pediatric age group (<18) with donors of age 60 years or older.





**Figure 2. | Adjusted risk of graft failure hazard ratio comparisons for donor and recipient age group among living donor kidney transplant recipients, 1998–2012.** Adjusted for calendar year as well as recipient race and ethnicity, ESRD cause, panel reactive antibody at transplant, previous transplant, years of ESRD, hepatitis C serology, and insurance. In addition, all models were adjusted for the following donor-recipient combinations: sex, obesity status (obese if body mass index  $\geq 30$ ), weight ratio, height ratio, and HLA mismatch.



**Figure 3. | Adjusted probability (and 95% confidence interval) of graft failure at 5 and 10 years by donor-recipient sex for recipients of living unrelated, living related, and deceased donor transplants, 1998–2012.** Adjusted for calendar year as well as recipient race and ethnicity, ESRD cause, panel reactive antibody at transplant, previous transplant, years of ESRD, hepatitis C serology, and insurance. In addition, all models were adjusted for the following donor-recipient combinations: age, obesity status (obese if body mass index  $\geq 30$ ), weight ratio, height ratio, and HLA mismatch. Each probability pertains to the average donor and recipient characteristic for each model. F, female; M, male.

**Table 6. Adjusted probability (and 95% confidence interval) of graft failure at 5 and 10 years by obesity of recipient and donor and donor type, 1998–2012<sup>a</sup>**

Donor Type <sup>a</sup>	Donor Obese? <sup>b</sup>	Recipient Obese? <sup>b</sup>	N	%	5 yr	10 yr
Living unrelated	No	No	15,043	46.5	14.6 (13.8 to 15.4)	31.5 (29.9 to 33.1)
	Yes	No	3687	11.4	16.0 (14.4 to 17.5)	31.4 (28.6 to 34.1)
Living related	No	Yes	5817	18.0	15.9 (14.6 to 17.3)	35.1 (32.4 to 37.8)
	Yes	Yes	2205	6.8	18.1 (16.1 to 20.0)	40.7 (36.7 to 44.4)
	No	No	25,463	44.9	15.4 (14.6 to 16.1)	33.5 (32.1 to 34.8)
	Yes	No	6516	11.5	15.9 (14.7 to 17.0)	35.6 (33.4 to 37.7)
Deceased donor	No	Yes	7277	12.8	16.3 (15.1 to 17.4)	35.0 (32.8 to 37.1)
	Yes	Yes	3555	6.3	17.9 (16.4 to 19.4)	40.6 (37.8 to 43.4)
	No	No	68,229	47.5	26.8 (26.4 to 27.3)	48.7 (48.1 to 49.4)
	Yes	No	19,948	13.9	28.0 (27.2 to 28.8)	50.5 (49.2 to 51.8)
	No	Yes	27,293	19.0	28.4 (27.7 to 29.1)	53.6 (52.4 to 54.7)
	Yes	Yes	9811	6.8	31.5 (30.4 to 32.7)	56.8 (54.9 to 58.7)

<sup>a</sup>Adjusted for transplant year, ESRD cause, panel reactive antibody at transplant, previous transplant, years of ESRD, hepatitis C serology, insurance, and recipient and donor race and ethnicity, donor history of cigarette use, and the following donor-recipient combinations: age, sex, weight ratio, height ratio, HLA mismatch, and ABO compatibility. Each probability pertains to the average donor and recipient characteristic for each model.

<sup>b</sup>Recipients with missing body mass index (BMI) and/or missing donor BMI are not shown (living unrelated LUR: *n*=5597, 17%; living related LR: *n*=13,848, 24%; deceased donor DD *n*=18,415, 13%)

be provided with information on the possibility of improving their expected outcomes through entering and obtaining a match with a donor in a KPD pool. Involvement of compatible pairs in this way would also enrich the KPD program by increasing the number of possible matches perhaps by potentially offsetting the deficiency of O donors commonly observed in KPD programs. Generally, we suggest that a candidate with a compatible donor consider the possibility of risk reduction through joining a KPD system. However, one

concern is that exchanges may be suggested to compatible pairs on the basis of compatibility with other pairs within the KPD pool, but the compatible pair would be unable to assess whether the recipient would improve his or her potential outcomes. In such cases, there might be some pressure, whether overt or implicit, to participate in an exchange for altruistic reasons. The calculator developed in this paper would offer valuable information for such compatible pairs to evaluate their options and to participate when it is to their

**Table 7. Kidney graft failure estimates for a 50-year-old man with three potential donors**

Characteristic <sup>a</sup>	Donor 1 (Sister)	Donor 2 (Unrelated)	Donor 3 (Unrelated)
Donor age, yr	55	25	35
Donor sex	Female	Male	Female
Donor BMI	Not obese	Not obese	Obese
Donor-recipient weight ratio	0.70	1.20	0.95
HLA	3 HLA MM 1 DR	2 HLA MM 2 DR	5 HLA MM 2 DR
Estimated graft failure at 5 yr <sup>b</sup> (95% confidence interval), %	16.0 (14.2 to 17.8)	9.8 (8.6 to 11.0)	13.6 (12.1 to 15.1)
Estimated graft failure at 10 yr <sup>c</sup> (95% confidence interval), %	39.6 (31.4 to 47.8)	30.2 (22.9 to 37.6)	36.2 (28.3 to 44.0)

BMI, body mass index; MM, mismatch.

<sup>a</sup>In these examples, all recipient and donor characteristics with the exception of transplant year not described are the reference characteristic found in Supplemental Table 1. The transplant year is 2008–2012, the most recent cohort, in these examples.

<sup>b</sup>To compute the probability of graft failure at 5 yr, use the parameter estimates and baseline survival curve found in Supplemental Table 1: Probability (graft failure at 5 yr)= $1-0.7995^A$  where  $A=\exp(0.0112 \times I[\text{related first-degree}]+0.0434 \times I[\text{related second-degree}]+0.0263 \times I[\text{recipient age } <13]+0.5365 \times I[\text{recipient age } 13-17]+0.4375 \times I[\text{recipient age } 18-29]-0.1087 \times I[\text{recipient age } 30-39]-0.2557 \times I[\text{recipient age } 50-59]-0.050 I[\text{recipient age } \geq 60]+ \dots + 0.396 \times I[\text{recipient hepatitis C serology positive}]-0.227 \times I[\text{insurance private primary payer}]-0.0748 \times I[\text{insurance other/missing}]-0.1098 \times I[\text{transplant year } 2003-2007]-0.3330 \times I[\text{transplant year } 2008-2012])$ , where  $I(A)$  is set to 1 if condition A applies (*i.e.*, if the recipient/donor possesses condition A), and otherwise it is set to 0. Our calculator does the computation at <https://kecc.shinyapps.io/SurvivalCalculator/>.

<sup>c</sup>The probability of graft failure at 10 yr is computed as follows. The probability of graft failure= $1 - \text{probability of graft survival}$ . Compute the probability of graft survival for the first 5 years (=F) and then compute the probability of graft failure for the second 5 years (=T). The probability of graft failure at 10 years= $1 - (F \times T)$ . Our calculator does the computation at <https://kecc.shinyapps.io/SurvivalCalculator/>.

advantage and to the advantage of one or more other candidates in the KPD pool. Provision of suitable decision support tools would be helpful; summarizing the potential for risk reduction in an existing pool or simulating risk reductions on the basis of characteristics of previous donors are possibilities. The presence of such compatible donors in the KPD pool could be accommodated through the use of existing algorithms fine-tuned to prioritize them with an advantage in selection.

Of particular interest is the advantage to male candidates who receive kidney transplants from male donors. This suggests that the rather common situation of a wife donating to her husband may be one where consideration should be given to entering a KPD program, where a male donor, perhaps with better matches in HLA and body size, might be found. Figure 4 shows the donor-recipient sex distribution by kidney transplant type for each donor and recipient combination. For LD transplants, female donor-to-male recipient is the largest group among all sex combinations. Among LUR, LR, and KPD groups, 46%, 31%, and 34% of transplants were female to male recipient; this can be compared with the DD group where only 24% of transplants were female to male. Note also that for all donor groups, there is no evidence of any advantage to a female candidate of a male donor. All else being equal, this suggests that there may be benefit for KPD programs to reserve male donors for male candidates whenever possible.

Compatible pairs with 5 or more HLA MMs might also consider joining a KPD pool. If, despite the MM with her or his donor, the candidate has a genotype that is relatively common in the population, there may be a preferable match with, say, only 1 or 2 HLA MMs in the KPD. This could result in a decrease in risk of from 20% to 31% (Table 1). The comparisons in Table 7 are on the basis of a model with “all else equal” and so need to be carefully interpreted when the factors investigated are typically associated with important

differences. For example, the apparent advantage in survival of LUR transplants may be mitigated to some degree by the fact that LR transplants typically have fewer HLA MMs than LUR transplants.

A use of the calculator that first motivated our investigations arises in the context of allocations in a KPD program where algorithms are developed to optimize the number of transplants or some other measure of utility (31–34). An alternative approach defines the value of a potential transplant from a given donor to a given recipient as the estimated probability that the graft would survive for 5 (or 10) years.

Recently, Massie *et al.* (2) considered a joint model with the aim of extending the kidney donor profile index for DDs to include LDs. Methodologic differences in their work include use of 10 versus 15 years of data, considering only adults with no previous transplants, and specifying models in which the effects of candidate characteristics are assumed to be the same for all donor types, a restriction that is not supported by the data (see differences in Table 1). They also do not include a time trend in their analyses, which could have major implications on estimating the association with graft survival of any donor or recipient characteristic whose distribution is changing over time. Because the kidney donor profile index only gives the percentile ranking among all donors and, as used with DD, does not reflect donor/recipient MMs or other interactions, we believe that our calculator (located at <https://kecc.shinyapps.io/SurvivalCalculator/>) gives metrics that are more relevant to the kidney transplant candidate.

We plan to develop further a DD calculator that can be used with the living donor calculator; this could aid in understanding the consequences of utilizing DDs as non-directed donors in instituting chains within a KPD program (19). This could be done without disadvantaging those on




Figure 4. | Donor-recipient sex distribution for living not biologically related, living biologically related, deceased, and kidney paired donation groups, 1998–2012.

the waiting list by having the chains end with a transplant to the DD waiting list. Such use of DDs has the potential to increase substantially the number of transplants.

This calculator is on the basis of 15 years of United States data during which transplant technology has changed, resulting in substantially better outcomes. We have predicted the outcomes as they would apply in the most recent 5-year period, but this may underestimate survival rates given this continuous improvement of outcomes. It should be noted, however, that relative differences due to most risk factors have not changed appreciably, so comparative statements are less affected by these secular trends.

As in many such studies (1,5,15–18), we have confined attention to graft survival so that the outcome corresponds to graft failure as indicated by return to dialysis or death without graft failure. We cannot determine the length of time the graft would have functioned had the patient lived when a patient dies or if graft failure was a cause of death. Thus, this endpoint has the advantage of being relatively unambiguous and seems an important one from a clinical perspective. However, it is comprised of two competing risks and these can be examined separately (1) to see to what extent the risk factors affect differently the rates of graft failure and death without graft failure. As has been noted elsewhere (1), transplantation of adolescent and young adult recipients is associated with a substantially higher rate of graft failure and a somewhat lower death rate. Similarly, the higher risk for black recipients is primarily due to graft failure. Females have a lower risk of graft failure than males, but a higher risk of death. In Supplemental Table 2, we have provided parameter estimates for a 5-year Cox model for death-censored graft failure and for death. The estimated probabilities of these events up to 5 years for donors 1–3 are given in Supplemental Table 3.

In conclusion, we believe that the calculator for the combined event of graft survival is of potential interest to kidney transplant candidates and clinicians, and could help guide decisions to choose among multiple compatible donors, or decisions of compatible pairs with respect to joining a KPD program.

#### Acknowledgments

This work was supported in part by the National Institute of Diabetes and Digestive and Kidney Diseases through grant number 1R01-DK093513. M.A.R. is supported in part by National Institute of Allergy and Infectious Diseases (NIAID) grants R21 AI-111579 and R01-AI090244. M.A.R. and A.B.L. are supported in part by Agency for Healthcare Research and Quality (AHRQ) grant R18 HS-020610.

Portions of this manuscript were presented in abstract form at the 2014 Annual Society of Nephrology Conference on November 14, 2014 in Philadelphia, Pennsylvania and at the 2016 American Transplant Congress on June 11, 2016 in Boston, Massachusetts.

The data reported here have been supplied by the Minneapolis Medical Research Foundation as the contractor for the Scientific Registry of Transplant Recipients (SRTR). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the SRTR or the United States government.

#### Disclosures

M.A.R. reports receiving grant support for the Alliance for Paired Donation from Novartis and Sanofi Pharmaceuticals and Optum.

#### References

1. Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Stewart DE, Cherikh WS, Wainright JL, Boyle G, Snyder JJ, Israni AK, Kasiske BL: OPTN/SRTR 2013 annual data report: Kidney. *Am J Transplant* 15[Suppl 2]: 1–34, 2015
2. Massie AB, Leanza J, Fahmy LM, Chow EK, Desai NM, Luo X, King EA, Bowring MG, Segev DL: A Risk index for living donor kidney transplantation. *Am J Transplant* 16: 2077–2084, 2016
3. Tullius SG, Tran H, Guleria I, Malek SK, Tilney NL, Milford E: The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome. *Ann Surg* 252: 662–674, 2010
4. Meier-Kriesche HU, Cibrik DM, Ojo AO, Hanson JA, Magee JC, Rudich SM, Leichtman AB, Kaplan B: Interaction between donor and recipient age in determining the risk of chronic renal allograft failure. *J Am Geriatr Soc* 50: 14–17, 2002
5. Tan JC, Kim JP, Chertow GM, Grumet FC, Desai M: Donor-recipient sex mismatch in kidney transplantation. *Gen Med* 9: 335–347.e2, 2012
6. Kwon OJ, Kwak JY: The impact of sex and age matching for long-term graft survival in living donor renal transplantation. *Transplant Proc* 36: 2040–2042, 2004
7. Øien CM, Reisaeter AV, Leivestad T, Dekker FW, Line PD, Os I: Living donor kidney transplantation: The effects of donor age and gender on short- and long-term outcomes. *Transplantation* 83: 600–606, 2007
8. Foster BJ, Dahhou M, Zhang X, Platt RW, Smith JM, Hanley JA: Impact of HLA mismatch at first kidney transplant on lifetime with graft function in young recipients. *Am J Transplant* 14: 876–885, 2014
9. Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM: Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. *N Engl J Med* 343: 1078–1084, 2000
10. Casey MJ, Wen X, Rehman S, Santos AH, Andreoni KA: Rethinking the advantage of zero-HLA mismatches in unrelated living donor kidney transplantation: Implications on kidney paired donation. *Transpl Int* 28: 401–409, 2015
11. Cacciola RA, Pujar K, Ilham MA, Puliatti C, Asderakis A, Chavez R: Effect of degree of obesity on renal transplant outcome. *Transplant Proc* 40: 3408–3412, 2008
12. Ditonno P, Lucarelli G, Impedovo SV, Spilotros M, Grandaliano G, Selvaggi FP, Bettocchi C, Battaglia M: Obesity in kidney transplantation affects renal function but not graft and patient survival. *Transplant Proc* 43: 367–372, 2011
13. Chung H, Lam VW, Yuen LP, Ryan BJ, O'Connell PJ, Chapman JR, Hawthorne WJ, Pleass HC: Renal transplantation: Better fat than thin. *J Surg Res* 194: 644–652, 2015
14. Giral M, Nguyen JM, Karam G, Kessler M, Hurault de Ligny B, Buchler M, Bayle F, Meyer C, Foucher Y, Martin ML, Daguin P, Souillou JP: Impact of graft mass on the clinical outcome of kidney transplants. *J Am Soc Nephrol* 16: 261–268, 2005
15. Giral M, Foucher Y, Karam G, Labruno Y, Kessler M, Hurault de Ligny B, Büchler M, Bayle F, Meyer C, Trehet N, Daguin P, Renaudin K, Moreau A, Souillou JP: Kidney and recipient weight incompatibility reduces long-term graft survival. *J Am Soc Nephrol* 21: 1022–1029, 2010
16. Kasiske BL, Snyder JJ, Gilbertson D: Inadequate donor size in cadaver kidney transplantation. *J Am Soc Nephrol* 13: 2152–2159, 2002
17. Fuggle SV, Allen JE, Johnson RJ, Collett D, Mason PD, Dudley C, Rudge CJ, Bradley JA, Watson CJ; Kidney Advisory Group of NHS Blood and Transplant: Factors affecting graft and patient survival after live donor kidney transplantation in the UK. *Transplantation* 89: 694–701, 2010
18. Ahmadi SF, Zahmatkesh G, Streja E, Molnar MZ, Rhee CM, Kovesdy CP, Gillen DL, Steiner S, Kalantar-Zadeh K: Body mass index and mortality in kidney transplant recipients: A systematic review and meta-analysis. *Am J Nephrol* 40: 315–324, 2014
19. Melcher ML, Roberts JP, Leichtman AB, Roth AE, Rees MA: Utilization of deceased donor kidneys to initiate living donor chains. *Am J Transplant* 16: 1367–1370, 2016
20. Gratwohl A, Döhler B, Stern M, Opelz G: H-Y as a minor histocompatibility antigen in kidney transplantation: A retrospective cohort study. *Lancet* 372: 49–53, 2008
21. Heaphy EL, Goldfarb DA, Poggio ED, Buccini LD, Flechner SM, Schold JD: The impact of deceased donor kidney risk significantly varies by recipient characteristics. *Am J Transplant* 13: 1001–1011, 2013

22. Van Arendonk KJ, Orandi BJ, James NT, Segev DL, Colombani PM: Living unrelated renal transplantation: A good match for the pediatric candidate? *J Pediatr Surg* 48: 1277–1282, 2013
23. Park K, Moon JI, Kim SI, Kim YS: Exchange donor program in kidney transplantation. *Transplantation* 67: 336–338, 1999
24. Rapaport FT: The case for a living emotionally related international kidney donor exchange registry. *Transplant Proc* 18 [Suppl 2]: 5–9, 1986
25. Gentry SE, Montgomery RA, Segev DL: Kidney paired donation: Fundamentals, limitations, and expansions. *Am J Kidney Dis* 57: 144–151, 2011
26. Wallis CB, Samy KP, Roth AE, Rees MA: Kidney paired donation. *Nephrol Dial Transplant* 26: 2091–2099, 2011
27. Kalbfleisch JD, Prentice RL: *The Statistical Analysis of Failure Time Data*, 2nd Ed., New York, NY, John Wiley and Sons, 2011
28. Wolfe RA, McCullough KP, Leichtman AB: Predictability of survival models for waiting list and transplant patients: Calculating LYFT. *Am J Transplant* 9: 1523–1527, 2009
29. Cook NR: Use and misuse of the receiver operating characteristic curve in risk prediction. *Circulation* 115: 928–935, 2007
30. Rao PS, Schaubel DE, Guidinger MK, Andreoni KA, Wolfe RA, Merion RM, Port FK, Sung RS: A comprehensive risk quantification score for deceased donor kidneys: The kidney donor risk index. *Transplantation* 88: 231–236, 2009
31. Roth AE, Sonmez T, Unver MU: Pairwise kidney exchange. *J Econ Theory* 125: 151–188, 2005
32. Roth AE, Sönmez T, Unver MU, Delmonico FL, Saidman SL: Utilizing list exchange and nondirected donation through ‘chain’ paired kidney donations. *Am J Transplant* 6: 2694–2705, 2006
33. Li Y, Song PX, Zhou Y, Leichtman AB, Rees MA, Kalbfleisch JD: Optimal decisions for organ exchanges in a kidney paired donation program. *Stat Biosci* 6: 85–104, 2014
34. Bray M, Wang W, Song PX, Leichtman AB, Rees MA, Ashby VB, Eikstadt R, Goulding A, Kalbfleisch JD: Planning for uncertainty and fallbacks can increase the number of transplants in a kidney-paired donation program. *Am J Transplant* 15: 2636–2645, 2015

**Received:** September 2, 2016 **Accepted:** March 27, 2017

Published online ahead of print. Publication date available at [www.cjasn.org](http://www.cjasn.org).

This article contains supplemental material online at <http://cjasn.asnjournals.org/lookup/suppl/doi:10.2215/CJN.09330916/-/DCSupplemental>.



## Supplemental Tables

**Table S1. Regression Parameter Estimates in the Cox Proportional Hazards Model for Graft Survival for the First and the Second Five-Year Periods Post-Transplant**

Characteristic	Group	Parameter Estimates			
		First 5-years		Second 5-years	
		Estimate	SE	Estimate	SE
Living Donor Type	Unrelated (Ref)	0.0000	0.0000	0.0000	0.0000
	Related-1st Degree	0.0112	0.0248	0.0493	0.0331
	Related-2nd or Higher Degree	0.0434	0.0357	0.0408	0.0490
Recipient Age	< 13	0.0263	0.7981	1.3055	1.0089
	13-17	0.5365	0.6445	-0.4378	1.0982
	18-29	0.4375	0.3877	1.2684	0.5361
	30-39	-0.1087	0.4500	0.8588	0.6087
	40-49 (Ref)	0.0000	0.0000	0.0000	0.0000
	50-59	-0.2557	0.4138	1.0170	0.5220
	60+	-0.0748	0.5302	1.6204	0.6582
Among Recipients Age < 12	Donor Age (continuous)	-0.0078	0.0273	-0.0360	0.0342
	Donor Age > 30	-0.0158	0.0425	0.0968	0.0515
	Donor Age >40	0.0608	0.0449	-0.0794	0.0480
	Donor Age > 50	-0.0205	0.0774	0.1326	0.0696
Among Recipients Age 13-17	Donor Age (continuous)	0.0011	0.0224	0.0640	0.0388
	Donor Age > 30	-0.0110	0.0378	-0.1099	0.0609
	Donor Age >40	-0.0066	0.0325	0.0396	0.0486
	Donor Age > 50	0.0700	0.0428	0.0935	0.0577
Among Recipients Age 18-29	Donor Age (continuous)	-0.0151	0.0101	-0.0227	0.0147
	Donor Age > 30	0.0633	0.0176	0.0898	0.0257
	Donor Age >40	-0.0704	0.0172	-0.0960	0.0249
	Donor Age > 50	0.0342	0.0214	0.0188	0.0328
	Donor Age >60	0.0854	0.0581	-0.3487	0.3172
Among Recipients Age 30-39	Donor Age (continuous)	-0.0056	0.0125	-0.0152	0.0171
	Donor Age > 30	0.0117	0.0185	0.0162	0.0251
	Donor Age >40	0.0154	0.0167	0.0221	0.0229
	Donor Age > 50	-0.0169	0.0218	-0.0098	0.0309
	Donor Age >60	0.0732	0.0360	-0.0111	0.0584
Among Recipients Age 40-49	Donor Age (continuous)	-0.0113	0.0114	0.0188	0.0150
	Donor Age > 30	0.0222	0.0186	-0.0393	0.0242
	Donor Age >40	-0.0225	0.0148	0.0425	0.0192

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Characteristic	Group	Parameter Estimates			
		First 5-years		Second 5-years	
		Estimate	SE	Estimate	SE
	Donor Age > 50	0.0627	0.0189	0.0050	0.0245
	Donor Age >60	-0.0620	0.0360	0.0059	0.0419
Among Recipients Age 50-59	Donor Age (continuous)	0.0003	0.0109	-0.0126	0.0130
	Donor Age > 30	0.0049	0.0173	0.0054	0.0209
	Donor Age >40	-0.0012	0.0155	0.0212	0.0195
	Donor Age > 50	0.0239	0.0153	0.0040	0.0200
	Donor Age >60	0.0103	0.0304	0.0249	0.0414
Among Recipients Age 60+	Donor Age (continuous)	0.0014	0.0160	-0.0229	0.0192
	Donor Age > 30	0.0115	0.0218	0.0399	0.0265
	Donor Age >40	0.0049	0.0143	0.0097	0.0180
	Donor Age > 50	-0.0174	0.0150	-0.0426	0.0205
	Donor Age >60	0.0472	0.0180	0.0579	0.0285
Donor-Recipient Type	Female-Female	0.0458	0.0265	-0.0561	0.0354
	Male-Female	0.0502	0.0328	-0.0125	0.0425
	Female-Male (Ref)	0.0000	0.0000	0.0000	0.0000
	Male-Male	-0.1221	0.0276	-0.0469	0.0354
HLA ABDR Mismatch	0 HLA MM	-0.4623	0.0411	-0.4616	0.0515
	1-2 HLA MM, 0 DR MM	-0.0892	0.0312	-0.1842	0.0413
	1-2 HLA MM, Any DR MM	-0.0688	0.0288	-0.0344	0.0364
	3-4 HLA MM, 0 DR MM	-0.0581	0.0653	-0.1595	0.0926
	3-4 HLA MM, Any DR MM (Ref)	0.0000	0.0000	0.0000	0.0000
	5,6, Missing HLA MM	0.0662	0.0242	0.0877	0.0330
Recipient BMI	Not Obese (<30) (Ref)	0.0000	0.0000	0.0000	0.0000
	Obese (> 30)	0.1469	0.0257	0.1484	0.0345
	Missing	0.1224	0.0394	0.1044	0.0470
Donor BMI	Not Obese (<30) (Ref)	0.0000	0.0000	0.0000	0.0000
	Obese (> 30)	0.0654	0.0254	0.0929	0.0346
	Missing	0.0381	0.0524	0.0807	0.0643
Donor-recipient Weight Ratio	< 0.75	0.0903	0.0349	0.0235	0.0486
	0.75-0.90	0.0083	0.0302	0.0571	0.0406
	0.90-1.15 (Ref)	0.0000	0.0000	0.0000	0.0000
	> 1.15	0.0047	0.0286	0.0078	0.0383
	Missing	0.0857	0.0452	0.0074	0.0557
Donor-Recipient Height Ratio	< 0.94	0.0943	0.0347	0.0342	0.0478
	0.94-1.00	0.0067	0.0301	0.0196	0.0410
	1.00-1.06 (Ref)	0.0000	0.0000	0.0000	0.0000
	> 1.06	-0.0269	0.0330	0.0011	0.0447

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Characteristic	Group	Parameter Estimates			
		First 5-years		Second 5-years	
		Estimate	SE	Estimate	SE
	Missing	-0.0600	0.0511	-0.0489	0.0631
Recipient Race	White	0.0000	0.0000	0.0000	0.0000
	Black	0.1984	0.0503	0.1448	0.0784
	Hispanic	-0.1068	0.0505	-0.1684	0.0700
	Other	-0.3160	0.0484	-0.4079	0.0664
Donor Race	Not Black or Hispanic (Ref)	0.0000	0.0000	0.0000	0.0000
	Black	0.1395	0.0522	0.0401	0.0810
	Hispanic	-0.1359	0.0508	-0.1642	0.0704
Donor History of Cigarette Use	No	0.0000	0.0000	0.0000	0.0000
	Yes	0.0771	0.0314	0.2257	0.0647
	Missing	0.1587	0.0288	0.1065	0.0429
ABO Compatibility	Not Incompatible	0.0000	0.0000	0.0000	0.0000
	Incompatible	0.3594	0.0748	0.0547	0.1357
PRA	0-9 (Ref)	0.0000	0.0000	0.0000	0.0000
	10-79	0.0965	0.0286	0.1397	0.0411
	80+	0.3464	0.0549	0.2660	0.0939
	Missing	-0.0939	0.0581	-0.0258	0.0774
Recipient Diagnosis	Not Diabetes (Ref)	0.0000	0.0000	0.0000	0.0000
	Diabetes	0.2732	0.0215	0.4675	0.0273
Previous Transplant	No (Ref)	0.0000	0.0000	0.0000	0.0000
	Yes	0.2246	0.0292	0.1608	0.0409
Time on dialysis	Pre-emptive Transplant	-0.4141	0.0269	-0.4092	0.0352
	0-1 years	-0.1731	0.0252	-0.1946	0.0334
	1-2 years (Ref)	0.0000	0.0000	0.0000	0.0000
	2-3 years	-0.0220	0.0337	0.0231	0.0455
	3+ years	0.0512	0.0311	-0.0234	0.0444
Recipient Hepatitis C Serology	Negative or Missing (Ref)	0.0000	0.0000	0.0000	0.0000
	Positive	0.3970	0.0445	0.3831	0.0630
Recipient insurance	Public Primary Payer (Ref)	0.0000	0.0000	0.0000	0.0000
	Private Primary Payer	-0.2266	0.0199	-0.2084	0.0264
	Other/Missing	-0.1160	0.0523	-0.2214	0.0716
Transplant Year	1998-2002 (Ref)	0.0000	0.0000	0.0000	0.0000
	2003-2007	-0.1098	0.0253	-0.1155	0.0285
	2008-2012	-0.3330	0.0381	-0.0762	0.1943

Baseline survival at first 5 years: 0.7995; at second 5 years: 0.8615

**Table S2. Regression Parameter Estimates in the Cox Proportional Hazards Models for Graft Survival (Censored at Death) and Death\* Based on Data Up to 5-Years Post Transplant**

Characteristic	Group	Parameter Estimates			
		Graft Survival (Censored at Death)		Patient Survival*	
		Estimate	SE	Estimate	SE
Living Donor Type	Unrelated (Ref)	0.0000	0.0000	0.0000	0.0000
	Related-1st Degree	-0.0044	0.0313	0.0485	0.0338
	Related-2nd or Higher Degree	0.0111	0.0442	0.0483	0.0513
Recipient Age	< 13	0.0039	0.9092	0.2958	1.3422
	13-17	1.0019	0.6927	-2.0730	1.6554
	18-29	0.8476	0.4476	-0.5893	0.6710
	30-39	-0.0082	0.5259	-0.6933	0.7164
	40-49 (Ref)	0.0000	0.0000	0.0000	0.0000
	50-59	-0.6343	0.5534	0.0346	0.5244
	60+	-0.5335	0.8410	0.7895	0.6107
Among Recipients Age < 12	Donor Age (continuous)	0.0023	0.0306	-0.0486	0.0481
	Donor Age > 30	-0.0297	0.0473	0.0064	0.0802
	Donor Age >40	0.0745	0.0492	0.1189	0.0901
	Donor Age > 50	-0.0174	0.0814	-0.1214	0.1667
Among Recipients Age 13-17	Donor Age (continuous)	-0.0032	0.0231	0.0415	0.0614
	Donor Age > 30	-0.0023	0.0390	-0.0677	0.1001
	Donor Age >40	-0.0112	0.0335	0.0033	0.0879
	Donor Age > 50	0.0766	0.0440	-0.0841	0.1962
Among Recipients Age 18-29	Donor Age (continuous)	-0.0193	0.0106	-0.0175	0.0215
	Donor Age > 30	0.0738	0.0184	0.0353	0.0384
	Donor Age >40	-0.0771	0.0179	-0.0273	0.0396
	Donor Age > 50	0.0337	0.0226	0.0539	0.0463
	Donor Age >60	0.0607	0.0662	0.0812	0.1041
Among Recipients Age 30-39	Donor Age (continuous)	-0.0016	0.0140	-0.0095	0.0218
	Donor Age > 30	0.0048	0.0207	0.0320	0.0319
	Donor Age >40	0.0203	0.0188	-0.0217	0.0282
	Donor Age > 50	-0.0109	0.0246	0.0104	0.0373
	Donor Age >60	0.0529	0.0413	0.0571	0.0589
Among Recipients Age 40-49	Donor Age (continuous)	-0.0112	0.0140	-0.0157	0.0154
	Donor Age > 30	0.0256	0.0229	0.0088	0.0256
	Donor Age >40	-0.0233	0.0182	0.0040	0.0210
	Donor Age > 50	0.0551	0.0232	0.0398	0.0269
	Donor Age >60	-0.0386	0.0435	-0.0563	0.0518
	Donor Age (continuous)	0.0063	0.0156	-0.0076	0.0130

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Characteristic	Group	Parameter Estimates			
		Graft Survival (Censored at Death)		Patient Survival*	
		Estimate	SE	Estimate	SE
Among Recipients Age 50-59	Donor Age > 30	-0.0181	0.0248	0.0277	0.0206
	Donor Age >40	0.0434	0.0223	-0.0378	0.0183
	Donor Age > 50	-0.0133	0.0213	0.0474	0.0187
	Donor Age >60	0.0306	0.0409	-0.0099	0.0394
Among Recipients Age 60+	Donor Age (continuous)	-0.0044	0.0275	-0.0196	0.0169
	Donor Age > 30	0.0112	0.0381	0.0451	0.0232
	Donor Age >40	0.0141	0.0255	-0.0132	0.0153
	Donor Age > 50	0.0072	0.0259	-0.0191	0.0162
	Donor Age >60	0.0165	0.0289	0.0554	0.0198
Donor-Recipient Type	Female-Female	0.1905	0.0328	-0.1111	0.0375
	Male-Female	0.2050	0.0402	-0.1237	0.0466
	Female-Male (Ref)	0.0000	0.0000	0.0000	0.0000
	Male-Male	-0.1516	0.0357	-0.0902	0.0369
HLA ABDR Mismatch	0 HLA MM	-0.6096	0.0529	-0.2880	0.0551
	1-2 HLA MM, 0 DR MM	-0.1623	0.0399	-0.0402	0.0426
	1-2 HLA MM, Any DR MM	-0.0985	0.0365	-0.0513	0.0395
	3-4 HLA MM, 0 DR MM	-0.1672	0.0863	0.0029	0.0880
	3-4 HLA MM, Any DR MM (Ref)	0.0000	0.0000	0.0000	0.0000
	5,6, Missing HLA MM	0.1022	0.0302	0.0525	0.0333
Recipient BMI	Not Obese (<30) (Ref)	0.0000	0.0000	0.0000	0.0000
	Obese (> 30)	0.1668	0.0330	0.1117	0.0342
	Missing	0.0763	0.0495	0.0694	0.0536
Donor BMI	Not Obese (<30) (Ref)	0.0000	0.0000	0.0000	0.0000
	Obese (> 30)	0.0762	0.0319	0.0359	0.0352
	Missing	0.0438	0.0660	-0.0506	0.0709
Donor-recipient Weight Ratio	< 0.75	0.1010	0.0446	0.0513	0.0474
	0.75-0.90	0.0033	0.0386	0.0020	0.0410
	0.90-1.15 (Ref)	0.0000	0.0000	0.0000	0.0000
	> 1.15	-0.0930	0.0356	0.1565	0.0397
	Missing	-0.0010	0.0563	0.2207	0.0618
Donor-Recipient Height Ratio	< 0.94	0.1265	0.0441	0.0676	0.0476
	0.94-1.00	0.0382	0.0382	0.0034	0.0411
	1.00-1.06 (Ref)	0.0000	0.0000	0.0000	0.0000
	> 1.06	-0.0158	0.0410	-0.0137	0.0469
	Missing	-0.0154	0.0646	0.0082	0.0695
Recipient Race	White	0.0000	0.0000	0.0000	0.0000
	Black	0.3694	0.0600	-0.0861	0.0747



Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Characteristic	Group	Parameter Estimates			
		Graft Survival (Censored at Death)		Patient Survival*	
		Estimate	SE	Estimate	SE
Donor Race	Hispanic	0.0105	0.0620	-0.3473	0.0731
	Other	-0.2432	0.0611	-0.4812	0.0670
	Not Black or Hispanic (Ref)	0.0000	0.0000	0.0000	0.0000
	Black	0.2035	0.0622	0.0269	0.0777
	Hispanic	-0.1086	0.0625	-0.2078	0.0730
Donor History of Cigarette Use	No	0.0000	0.0000	0.0000	0.0000
	Yes	0.1312	0.0401	0.0104	0.0435
	Missing	0.1859	0.0364	0.1585	0.0399
ABO Compatibility	Not Incompatible	0.0000	0.0000	0.0000	0.0000
	Incompatible	0.4304	0.0916	0.2538	0.1065
PRA	0-9 (Ref)	0.0000	0.0000	0.0000	0.0000
	10-79	0.1287	0.0355	0.0787	0.0396
	80+	0.4307	0.0655	0.2724	0.0800
	Missing	-0.1415	0.0744	-0.0605	0.0788
Recipient Diagnosis	Not Diabetes (Ref)	0.0000	0.0000	0.0000	0.0000
	Diabetes	-0.0211	0.0310	0.5788	0.0263
Previous Transplant	No (Ref)	0.0000	0.0000	0.0000	0.0000
	Yes	0.1988	0.0358	0.2737	0.0414
Time on dialysis	Pre-emptive Transplant	-0.4016	0.0340	-0.4712	0.0368
	0-1 years	-0.1476	0.0316	-0.2381	0.0349
	1-2 years (Ref)	0.0000	0.0000	0.0000	0.0000
	2-3 years	-0.0947	0.0439	0.0819	0.0435
	3+ years	-0.0421	0.0398	0.1726	0.0409
Recipient Hepatitis C Serology	Negative or Missing (Ref)	0.0000	0.0000	0.0000	0.0000
	Positive	0.3548	0.0589	0.5183	0.0552
Recipient insurance	Public Primary Payer (Ref)	0.0000	0.0000	0.0000	0.0000
	Private Primary Payer	-0.1680	0.0253	-0.3418	0.0271
	Other/Missing	-0.1155	0.0638	-0.1525	0.0747
Transplant Year	1998-2002 (Ref)	0.0000	0.0000	0.0000	0.0000
	2003-2007	-0.0893	0.0316	-0.1975	0.0348
	2008-2012	-0.3489	0.0482	-0.3770	0.0525

Baseline death censored graft survival: 0.8778; baseline patient survival: 0.8655

\*Patients are not censored at graft failure.

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

**Table S3. Five-Year Estimates of Graft Failure (Censored at Death) and Death for a 50-year Old Male Candidate with 3 Potential Donors\***

<b>Characteristic*</b>	<b>Donor 1 (Sister)</b>	<b>Donor 2 (Unrelated)</b>	<b>Donor 3 (Unrelated)</b>
Donor Age	55 years	25 years	35 years
Donor Sex	Female	Male	Female
Donor BMI	Not Obese	Not Obese	Obese
Donor-Recipient Weight Ratio	0.70	1.20	0.95
HLA	3 HLA MM 1 DR	2 HLA MM 2 DR	5 HLA MM 2 DR
Estimated Probability of Graft Failure* (Confidence Interval)	8.3% (7.0%, 9.6%)	4.3% (3.6%, 5.1%)	6.4% (5.4%, 7.4%)
Estimated Probability of Death*(Confidence Interval)	10.2% (8.6%, 11.8%)	7.1% (5.9%, 8.3%)	9.4% (8.0%, 10.8%)

\*In these examples, all recipient and donor characteristics with the exception of Transplant Year not described are the reference characteristic found in Supplementary Table S2. The Transplant Year is 2008-2012, the most recent cohort, in these examples. For the estimated graft failure, patients are censored at death. For the estimated probability of death, patients are not censored at graft failure.